G. Kadiyala

Human like severe hypertriglyceridemia in a high fat fed chicken model

This study develops a chicken model of severe hypertriglyceridemia by feeding high fat diets, mimicking human conditions to study disease mechanisms and test therapies.

Robust acidic pH and digestive enzyme stability of anti-SarsCov2 IgY antibodies: Implications for treatment of viral transmission thru gastrointestinal, ocular, nasal and skin tissues

The paper evaluates the stability of anti-SARS-CoV-2 IgY antibodies at acidic pH and against trypsin digestion, supporting their use in treating viral transmission through acidic environments.

Targeted neutralizing IgY antibodies against SGLT1 glucose transporter reduce glucose uptake and improve glycemic profile in vivo

An Anti-diabetic Nutraceutical enhances muscle cell glucose uptake of cardiometabolic drugs

The paper tests an anti-diabetic nutraceutical's ability to enhance glucose uptake in muscle cells when combined with cardiometabolic drugs, showing potential for improved glucose control.

Nutraceutical supplement targeting multiple molecular steps synergistically enhances muscle glucose uptake and improves in vivo oral glucose disposal

This study shows a combination of vitamins improves glucose uptake and disposal in pre-diabetes and type 2 diabetes through multiple molecular targets.

A 3-Dimensional bioprinted human gut-liver axis model for studying Alcoholic Liver Disease

This study develops a 3D bioprinted gut-liver axis model to investigate how Cytolysin and ethanol together cause intestinal damage in Alcoholic Liver Disease.

Differential Activity of Repurposed Drugs as Receptor Binding Domain Antagonists for Omicron and Native Strains of SarsCov2

The paper tests repurposed drugs as antagonists of SARS-CoV-2 RBD binding, finding that iodine-containing drugs are ineffective against Omicron.

Edible formulations of chicken egg derived IgY antibodies neutralize SarsCoV2 Omicron RBD binding to human ACE2

This study develops edible IgY antibodies from chicken eggs that neutralize Omicron RBD binding to human ACE2 and formulates them into beverages for oral use.

Preparation of ingestible antibodies to neutralize the binding of SarsCoV2 RBD (receptor binding domain) to human ACE2 Receptor

This study produces chicken-derived IgY antibodies against SARS-CoV2 RBD to neutralize ACE2 binding, effective against the delta variant, and proposes their use as ingestible passive immunotherapy.